NASDAQ:SAVA

Cassava Sciences - SAVA Stock Forecast, Price & News

$20.19

-0.23 (-1.13%)

(As of 08/15/2022 12:00 AM ET)

Add

Compare

Today's Range: $19.75
▼
$20.95
50-Day Range: $16.33
▼
$30.85
52-Week Range: $13.84
▼
$124.79

Volume: 893,113 shs
Average Volume: 1.67 million shs
Market Capitalization: $809.58 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $129.50

Cassava Sciences MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 541.4% Upside
$129.50 Price Target
Short Interest: Bearish
28.51% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -0.82
Upright™ Environmental Score
News Sentiment: 0.39
Based on 11 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.93) to ($1.29) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

600th out of 1,125 stocks

Pharmaceutical Preparations Industry

304th out of 554 stocks

3.3

Analyst's Opinion

Consensus Rating
Cassava Sciences has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.
Price Target Upside/Downside
According to analysts' consensus price target of $129.50, Cassava Sciences has a forecasted upside of 541.4% from its current price of $20.19.
Amount of Analyst Coverage
Cassava Sciences has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
28.51% of the outstanding shares of Cassava Sciences have been sold short.
Short Interest Ratio / Days to Cover
Cassava Sciences has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Cassava Sciences has recently increased by 12.28%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Cassava Sciences does not currently pay a dividend.
Dividend Growth
Cassava Sciences does not have a long track record of dividend growth.

4.7

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Cassava Sciences has received a 74.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for Alzheimer" and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Cassava Sciences is -0.82.

3.0

News and Social Media Coverage

News Sentiment
Cassava Sciences has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 11 news articles for Cassava Sciences this week, compared to 9 articles on an average week.
Social Mentions This Week
MarketBeat has tracked 1 reddit mention for Cassava Sciences this week, compared to 9 mentions on an average week.
Search Interest
40 people have searched for SAVA on MarketBeat in the last 30 days. This is an increase of 8% compared to the previous 30 days.
MarketBeat Follows
33 people have added Cassava Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 136% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Cassava Sciences insiders have not sold or bought any company stock.
Percentage Held by Insiders
10.10% of the stock of Cassava Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 34.01% of the stock of Cassava Sciences is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Cassava Sciences are expected to grow in the coming year, from ($1.93) to ($1.29) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Cassava Sciences is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Cassava Sciences is -13.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Cassava Sciences has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

Cassava Sciences Stock Performance

Shares of Cassava Sciences stock opened at $20.42 on Monday. Cassava Sciences has a twelve month low of $13.84 and a twelve month high of $124.80. The business has a 50-day moving average price of $24.05 and a 200-day moving average price of $29.84.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. HC Wainwright reaffirmed a "buy" rating on shares of Cassava Sciences in a report on Thursday, August 4th. B. Riley cut their price target on Cassava Sciences from $58.00 to $44.00 and set a "buy" rating for the company in a research note on Thursday.

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Stock News Headlines

August 15, 2022 | americanbankingnews.com

B. Riley Trims Cassava Sciences (NASDAQ:SAVA) Target Price to $44.00

August 12, 2022 | americanbankingnews.com

Financial Contrast: Cassava Sciences (NASDAQ:SAVA) vs. Pasithea Therapeutics (NASDAQ:KTTA)

August 11, 2022 | seekingalpha.com

Cassava's Simufilam And Acetylcholinesterase Inhibitors: Similar Results

August 8, 2022 | msn.com

What Is Going on With Cassava Sciences (SAVA) Stock Today?

August 7, 2022 | americanbankingnews.com

HC Wainwright Reaffirms "Buy" Rating for Cassava Sciences (NASDAQ:SAVA)

August 5, 2022 | uk.investing.com

Cassava Sciences Reports Second Quarter Financial Results, Interim Analysis of Open-label Study

August 3, 2022 | barrons.com

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Cassava Sciences, Inc. (SAVA) and Encourages Long-Term Investors to Contact the Firm

August 3, 2022 | finance.yahoo.com

Cassava Sciences Reports Second Quarter Financial Results for 2022, Mid-year Corporate Update and Interim Analysis of Open-label Study

July 28, 2022 | reuters.com

Exclusive: Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

July 27, 2022 | marketwatch.com

Cassava Sciences Shares Tumble Premarket After Report of Criminal Probe >SAVA

July 27, 2022 | finance.yahoo.com

Cassava Sciences Shares Plunge After Criminal Investigation Report

July 27, 2022 | finance.yahoo.com

Cassava's stock dives 21% after report citing alleged criminal probe of data from Alzheimer's drug trial

July 27, 2022 | finance.yahoo.com

Cassava Sciences Responds to Media Reports

July 27, 2022 | finance.yahoo.com

UPDATE 1-Illumina offers patent licences to rivals, patent truce with BGI -sources

July 27, 2022 | seekingalpha.com

Cassava Sciences sheds 44% on report of criminal probe linked to Alzheimer’s drug

July 27, 2022 | markets.businessinsider.com

Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy

July 27, 2022 | msn.com

EXCLUSIVE Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

July 27, 2022 | finance.yahoo.com

Exclusive-Cassava Sciences faces U.S. criminal probe tied to Alzheimer's drug, sources say

July 27, 2022 | finance.yahoo.com

Cassava's stock dives 24% after report citing alleged criminal probe of data from Alzheimer's drug trial

July 26, 2022 | msn.com

Decades of Alzheimer's Research Allegedly Based on Fabricated Data

July 21, 2022 | msn.com

Amid flood of Alzheimer's research, questionable conduct persists

July 20, 2022 | apnews.com

Bragar Eagel & Squire, P.C. Is Investigating Cassava, Hannon Armstrong, and Nio and Encourages Investors to Contact the Firm

June 23, 2022 | nasdaq.com

SAVA August 5th Options Begin Trading

June 16, 2022 | finance.yahoo.com

Cassava Sciences, Inc. (SAVA) Stock Moves -1.38%: What You Should Know

June 6, 2022 | markets.businessinsider.com

5 Short Squeeze Candidates To Watch This Week: Cassava Sciences Tops List, GameStop Short Interest And Cost To Borrow Rise

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive SAVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cassava Sciences and its competitors with MarketBeat's FREE daily newsletter.

SAVA Company Calendar

Last Earnings: 11/10/2021
Today: 8/15/2022
Next Earnings (Estimated): 11/09/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:SAVA
CUSIP: N/A
CIK: 1069530
Web: www.cassavasciences.com
Phone: (512) 501-2444
Fax: 512-501-0414
Employees: 24
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $129.50
High Stock Price Forecast: $215.00
Low Stock Price Forecast: $44.00
Forecasted Upside/Downside: +541.4%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.51)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-32,380,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -24.81%
Return on Assets: -23.93%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 23.41
Quick Ratio: 23.41

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.35 per share
Price / Book: 3.18

Miscellaneous

Outstanding Shares: 40,098,000
Free Float: 36,048,000
Market Cap: $809.58 million
Optionable: Not Optionable
Beta: 0.68

Key Executives

Mr. Remi Barbier (Age 62)
Founder, Chairman, Pres & CEO
Comp: $1.74M
Mr. Eric J. Schoen (Age 54)
Chief Financial Officer
Comp: $776.93k
Dr. Nadav Friedmann M.D. (Age 79)
Ph.D., Chief Medical Officer & Director
Comp: $765k
Dr. James W. Kupiec M.D.
Chief Clinical Devel. Officer
Dr. George Thornton
Sr. VP of Technology
Mr. Michael Zamloot
Sr. VP of Technical Operations
Dr. Lindsay H. Burns Ph.D.
Sr. VP of Neuroscience

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

SAVA Stock - Frequently Asked Questions

Should I buy or sell Cassava Sciences stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cassava Sciences in the last year. There are currently 1 sell rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SAVA shares.
View SAVA analyst ratings or view top-rated stocks.
What is Cassava Sciences' stock price forecast for 2022?: 4 brokers have issued 12 month target prices for Cassava Sciences' stock. Their SAVA share price forecasts range from $44.00 to $215.00. On average, they predict the company's stock price to reach $129.50 in the next twelve months. This suggests a possible upside of 541.4% from the stock's current price.
View analysts price targets for SAVA or view top-rated stocks among Wall Street analysts.
How have SAVA shares performed in 2022?: Cassava Sciences' stock was trading at $43.70 at the start of the year. Since then, SAVA stock has decreased by 53.8% and is now trading at $20.19.
View the best growth stocks for 2022 here.
When is Cassava Sciences' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our SAVA earnings forecast.
How were Cassava Sciences' earnings last quarter?: Cassava Sciences, Inc. (NASDAQ:SAVA) issued its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.15) by $0.09.
When did Cassava Sciences' stock split?: Shares of Cassava Sciences reverse split before market open on Wednesday, May 10th 2017. The 1-7 reverse split was announced on Monday, May 8th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

What other stocks do shareholders of Cassava Sciences own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Cassava Sciences investors own include Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Novavax (NVAX), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), NIO (NIO), DURECT (DRRX), Tesla (TSLA), OPKO Health (OPK) and Alibaba Group (BABA).
What is Cassava Sciences' stock symbol?: Cassava Sciences trades on the NASDAQ under the ticker symbol "SAVA."
Who are Cassava Sciences' major shareholders?: Cassava Sciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (0.00%), Group One Trading L.P. (0.00%), Northern Trust Corp (0.89%), Sculptor Capital LP (0.00%), JPMorgan Chase & Co. (0.14%) and SG Americas Securities LLC (0.00%). Insiders that own company stock include Eric Schoen, Remi Barbier and Sanford Robertson.
View institutional ownership trends.
How do I buy shares of Cassava Sciences?: Shares of SAVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Cassava Sciences' stock price today?: One share of SAVA stock can currently be purchased for approximately $20.19.
How much money does Cassava Sciences make?: Cassava Sciences (NASDAQ:SAVA) has a market capitalization of $809.58 million. The company earns $-32,380,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis.
How can I contact Cassava Sciences?: Cassava Sciences' mailing address is 7801 N CAPITAL OF TEXAS HIGHWAY SUITE 260, AUSTIN TX, 78731. The official website for the company is www.cassavasciences.com. The company can be reached via phone at (512) 501-2444, via email at ir@paintrials.com, or via fax at 512-501-0414.

This page (NASDAQ:SAVA) was last updated on 8/15/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Cassava Sciences - SAVA Stock Forecast, Price & News

Cassava Sciences MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Social Mentions This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Cassava Sciences (NASDAQ:SAVA) Stock

Cassava Sciences Stock Performance

Analysts Set New Price Targets

SAVA Stock News Headlines

SAVA Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

SAVA Stock - Frequently Asked Questions

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™